Author

Laurent Peyrin-Biroulet

THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A GLOBAL UC PATIENT SURVEY
THE IMPACT OF THE COVID-19 PANDEMIC ON PATIENTS WITH ULCERATIVE COLITIS: RESULTS FROM A GLOBAL UC PATIENT SURVEY

UEG Week+ | Interview with Late breaking abstract presenter
UEG Week+ | Interview with Late breaking abstract presenter

Laurent Peyrin-Biroulet  et al.

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH MODERATE TO SEVERE ISOLATED PROCTITIS RELATIVE TO THOSE WITH MORE EXTENSIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Laurent Peyrin-Biroulet  et al.

CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL
CLINICAL AND ENDOSCOPIC OUTCOMES WITH USTEKINUMAB IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE LONG-TERM EXTENSION PERIOD OF THE STARDUST TRIAL

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Laurent Peyrin-Biroulet  et al.

RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY
RELATIONSHIP BETWEEN HISTO-ENDOSCOPIC MUCOSAL HEALING AND BASELINE CHARACTERISTICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS RECEIVING FILGOTINIB IN THE PHASE 2B/3 SELECTION STUDY

Laurent Peyrin-Biroulet  et al.

EFFECT OF USTEKINUMAB MAINTENANCE THERAPY ON STOOL FREQUENCY AND RECTAL BLEEDING THROUGH 2 YEARS IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS
EFFECT OF USTEKINUMAB MAINTENANCE THERAPY ON STOOL FREQUENCY AND RECTAL BLEEDING THROUGH 2 YEARS IN THE UNIFI PHASE 3 STUDY IN ULCERATIVE COLITIS

Laurent Peyrin-Biroulet  et al.

DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY–NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION
DURABILITY OF OZANIMOD RESPONSE BY BASELINE ENDOSCOPIC DISEASE ACTIVITY IN ADVANCED THERAPY–NAIVE PATIENTS WITH ULCERATIVE COLITIS UNCONTROLLED ON CONVENTIONAL THERAPIES: INTERIM ANALYSIS OF THE TRUE NORTH OPEN-LABEL EXTENSION

Laurent Peyrin-Biroulet  et al.

Dynamic management of CD: reaching a new dimension in patient care (Janssen)
Dynamic management of CD: reaching a new dimension in patient care (Janssen)

Laurent Peyrin-Biroulet  et al.

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12

Laurent Peyrin-Biroulet  et al.

Ulcerative colitis: Today, tomorrow and the future (Gilead & Galapagos)
Ulcerative colitis: Today, tomorrow and the future (Gilead & Galapagos)

Laurent Peyrin-Biroulet  et al.

OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH
OZANIMOD IS AN EFFECTIVE ORAL TREATMENT FOR PATIENTS WITH ULCERATIVE COLITIS REGARDLESS OF MODERATE OR SEVERE ENDOSCOPIC DISEASE ACTIVITY: A POST HOC ANALYSIS OF TRUE NORTH

Laurent Peyrin-Biroulet  et al.

Ongoing evolution of new IBD therapies
Ongoing evolution of new IBD therapies

Laurent Peyrin-Biroulet

USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL
USTEKINUMAB IMPROVES HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH MODERATE-TO-SEVERE CROHN’S DISEASE: RESULTS UP TO WEEK 104 OF THE STARDUST TRIAL

Therapeutic Strategies in Crohn’s Disease: Does Pathophysiology Matter? (Takeda Pharmaceuticals International AG)
Therapeutic Strategies in Crohn’s Disease: Does Pathophysiology Matter? (Takeda Pharmaceuticals International AG)

Laurent Peyrin-Biroulet  et al.

EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL
EFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIALEFFICACY OF FILGOTINIB IN PATIENTS WITH ULCERATIVE COLITIS BY LINE OF THERAPY IN THE PHASE 2B/3 SELECTION TRIAL

Laurent Peyrin-Biroulet  et al.

Planning for the long distance: Caring for patients with inflammatory bowel disease (Fresenius Kabi)
Planning for the long distance: Caring for patients with inflammatory bowel disease (Fresenius Kabi)

Laurent Peyrin-Biroulet  et al.

FUTURE IBD: The emerging role of the IL-23 inhibitor class in Crohn’s disease (AbbVie)
FUTURE IBD: The emerging role of the IL-23 inhibitor class in Crohn’s disease (AbbVie)

Laurent Peyrin-Biroulet  et al.

Practice makes perfect: a holistic approach to remission in the clinic (Galapagos)
Practice makes perfect: a holistic approach to remission in the clinic (Galapagos)

Laurent Peyrin-Biroulet  et al.

The New Treatment Platform of Subcutaneous TNF Inhibitors in Inflammatory Bowel Disease (Celltrion Healthcare)
The New Treatment Platform of Subcutaneous TNF Inhibitors in Inflammatory Bowel Disease (Celltrion Healthcare)

Laurent Peyrin-Biroulet  et al.

Item 1 - 20 / 115
1
2 3 4 5 6